Desperate patients get early access to experimental cachexia drug
NCT ID NCT07399015
First seen Feb 19, 2026 · Last updated Jun 23, 2026 · Updated 16 times
Summary
This expanded access program allows seriously ill adults with advanced pancreatic cancer and severe weight loss (cachexia) to receive an experimental drug called mifomelatide. Patients get a daily injection for up to 13 weeks. The goal is to help manage cachexia when no other treatments are available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PDAC are added.
Genom att skicka in godkänner du våra Användarvillkor
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
mifomelatide
What this could lead to
If it works, this could help patients with advanced pancreatic cancer maintain weight and muscle, improving their quality of life.
What could go wrong
This is an expanded access program, not a formal trial, so results are not systematically collected. It may not work for everyone, and side effects are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.